UNSPSC 51141509: Vigabatrin

This classification denotes an anticonvulsant agent with the molecular formula C6H11NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GR120KRT6K, chemically known as 5-hexenoic acid, 4-amino- but generally known as vigabatrin, which bears US NIH Compound Identifier 5665. European Medicines Agency schedules Vigabatrin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00048MIG.

UNSPSC 51141509 Vigabatrin is a Commodity code, but the recent state and local opportunities tagged under it do not align with procurement of this specific antiepileptic drug. Instead, the code shows activity in broader pharmaceutical procurement — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing networks, and exploratory requests for information on direct-to-manufacturer prescription programs. State and local issuing bodies pursuing pharmaceutical procurement include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving participating states including Oregon). The scope of work spans emergency response pharmaceuticals, routine generic and OTC product distribution to government facilities, and emerging direct-to-manufacturer contracting models designed to bypass traditional pharmacy benefit managers and group purchasing organizations.

Recent opportunities reflect concentrated activity in Florida, Texas, and the upper Midwest through cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 (response deadline April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager arrangements. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with a response deadline of March 26, 2026, a July 1, 2026 contract effective date, and evaluation weighted 75 percent on price competitiveness. The mismatch between the code name (vigabatrin) and actual solicitation scope suggests these opportunities are tagged under the code as a catch-all for pharmaceutical procurement rather than representing demand for this particular drug product.